xbiotech品牌介绍

浏览量：3151

xbiotech

品牌简介

XBiotech认为，自然产生的单克隆抗体比非自然产生的单克隆抗体更安全、更有效、开发速度更快。该公司正在开发一系列针对炎症和传染性疾病的候选产品，并已开发出商业规模的制造技术和基础设施，以减少推出新候选产品的成本和时间。公司的发现和生产技术使XBiotech独特地适合于快速识别人类的中和抗体，并快速生产这些供人类使用的候选产品。
XBiotech的技术为我们提供了独特的能力来开发病毒或细菌感染性疾病的候选药物。我们的核心发现技术使直接从人类血液样本中提取抗体疗法得以快速开发，这些抗体疗法可用于中和传染病。我们的真人抗体疗法允许我们概括从免疫献血者获得的自然免疫的关键组成部分。我们将这一发现计划与一个新颖的制造平台相结合，以促进快速的商业规模生产。我们相信，我们在发现和创造新的、有效的传染病治疗方法，包括迅速应对传染病爆发方面的能力在制药行业是无与伦比的。

True Human™ monoclonal antibodies are derived from those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. XBiotech believes that naturally occurring monoclonal antibodies have the potential to be safer, more effective and faster to develop than their non-naturally occurring counterparts. The Company is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure that reduces the cost and time to launch new product candidates. The Company’s discovery and manufacturing technology makes XBiotech uniquely suited to rapidly identify neutralizing antibodies from humans and to quickly manufacture these product candidates for human use.

XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technology enables the rapid development of antibody therapies directly from human blood samples that can be used to neutralize infectious disease. Our True Human antibody therapies allow us to recapitulate key components of the natural immunity obtained from an immune blood donor. We combine this discovery program with a novel manufacturing platform to facilitate rapid commercial-scale production. We believe our capabilities are unparalleled in the pharmaceutical industry to discover and create novel, effective treatments for infectious disease, including rapidly addressing infectious disease outbreaks.